Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-cash Items (2017 - 2025)

UroGen Pharma (URGN) has disclosed Non-cash Items for 9 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 92.33% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, up 92.33%, and an annual FY2025 reading of $2.1 million, up 92.33% over the prior year.
  • Non-cash Items was $2.1 million for Q4 2025 at UroGen Pharma, up from $1.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $5.1 million in Q4 2023 and bottomed at $1.1 million in Q4 2024.
  • Average Non-cash Items over 5 years is $2.5 million, with a median of $2.1 million recorded in 2025.
  • The sharpest move saw Non-cash Items crashed 84.08% in 2021, then surged 168.63% in 2023.
  • Year by year, Non-cash Items stood at $2.1 million in 2021, then decreased by 11.15% to $1.9 million in 2022, then soared by 168.63% to $5.1 million in 2023, then tumbled by 78.72% to $1.1 million in 2024, then surged by 92.33% to $2.1 million in 2025.
  • Business Quant data shows Non-cash Items for URGN at $2.1 million in Q4 2025, $1.1 million in Q4 2024, and $5.1 million in Q4 2023.